Starting Olanzapine for Depression Augmentation
Start olanzapine at 2.5-5 mg once daily at bedtime when augmenting antidepressant therapy for treatment-resistant depression, with a target dose of 5-10 mg/day. 1
Initial Dosing Strategy
When initiating olanzapine as augmentation therapy for depression:
- Starting dose: 2.5-5 mg once daily at bedtime 1
- Target dose: 5-10 mg/day 2
- Maximum studied dose: 18 mg/day (when combined with fluoxetine) 2
- Timing: Administer at bedtime to leverage sedating effects 1
The FDA label supports starting at 5 mg when combining olanzapine with fluoxetine for treatment-resistant depression 2. However, clinical guidelines for other psychiatric conditions consistently recommend starting at 2.5 mg in older patients or those who may be pharmacodynamically sensitive 1.
Titration Schedule
Increase by 2.5-5 mg increments every 3-7 days based on tolerability and response 2. Research suggests:
- Most patients respond to doses between 5-15 mg/day 3
- Doses above 10-15 mg/day show minimal additional benefit 3
- The dose-response curve plateaus around 10 mg/day, with minimal slope increase at higher doses 3
Special Populations Requiring Lower Starting Doses
Start at 2.5 mg/day in:
- Older adults (≥65 years)
- Non-smoking females
- Patients with hepatic impairment
- Debilitated patients
- Those predisposed to hypotensive reactions 1, 2
Clinical Context for Use
Olanzapine augmentation should be considered when:
- At least 2 adequate antidepressant trials have failed 4, 5
- Patient has treatment-resistant depression with inadequate response to standard antidepressants 6, 7, 8
- Particularly effective in depression with melancholic features 6, 8
Research demonstrates that olanzapine augmentation can produce significant improvement, with one study showing MADRS scores decreasing from 17.1 at baseline to 8.1 at 4 weeks and 4.9 at 12 weeks (indicating full remission) 6.
Critical Safety Monitoring
Monitor closely for metabolic side effects:
- Weight gain: 24% of patients gain ≥7% body weight 9, 10
- Lipid abnormalities: Significant increases in total cholesterol, triglycerides, and LDL 10
- Glucose dysregulation: Monitor for hyperglycemia 2
- Orthostatic hypotension: Particularly during initial titration 1, 11
- Sedation/drowsiness: Common, especially early in treatment 11
Important Contraindications and Warnings
Avoid combining with benzodiazepines at high doses due to risk of oversedation and respiratory depression 11. When co-administration is necessary, use lower doses of both agents.
Do not use as monotherapy for depression - olanzapine is indicated only as augmentation to antidepressants or in combination with fluoxetine for bipolar depression 2.
Practical Prescribing Algorithm
- Confirm treatment resistance: Document at least 2 adequate antidepressant trials
- Assess risk factors: Age, smoking status, sex, hepatic function, cardiovascular status
- Start conservatively: 2.5 mg at bedtime (or 5 mg in younger, healthier patients)
- Titrate gradually: Increase by 2.5-5 mg every 3-7 days as tolerated
- Target therapeutic range: Aim for 5-10 mg/day initially
- Monitor response: Assess depressive symptoms at 2-4 weeks
- Consider dose adjustment: If inadequate response at 10 mg and plasma level <20 ng/mL, may increase to 15 mg 3
- Baseline and ongoing monitoring: Weight, lipids, glucose, blood pressure
Duration of Treatment
Once remission is achieved, continue at the lowest effective dose. Research shows significant improvement can occur within 4 weeks 6, though full assessment requires 6-8 weeks of treatment at therapeutic doses.